Randomized, multicenter, phase iii, open-label study of Alectinib versus Crizotinib in treatment-naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

Project: Research

Project Description

SERP Reference Number: HREC/14/SVH/106
SSA Reference Number: SSA/14/SHA/44
Monash Health HREC Ref: 14301X
StatusActive
Effective start/end date20/06/19 → 19/06/24
View all
View less

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • lung cancer